

**MINUTES OF THE CHARITABLE FUNDS  
 INVESTMENT PERFORMANCE REVIEW SUB-COMMITTEE**

**VELINDRE UNIVERSITY NHS TRUST – MICROSOFT TEAMS  
 TUESDAY 18TH MARCH 2025 AT 10:00AM**

<b>PRESENT:</b>	
Hilary Jones (HJ)	Independent Member
Matthew Bunce (MB)	Executive Director of Finance
<b>ATTENDEES:</b>	
Matt Bunce (MB)	Executive Director of Finance
Steve Coliandris (SC)	Head of Financial Planning & Reporting
Non Gwilym (NG)	Director of Corporate Governance
Niké Hooper-Collins (NHC)	Business Support Officer / Secretariat

<b>1.0.0</b>	<b>Standard Business</b> Led by Hilary Jones, Committee Acting Chair and Independent Member	<b>Action</b>
<b>1.1.0</b>	<b>In Attendance</b> Led by Hilary Jones  Attendance was as noted above.  The Chair welcomed Miranda Richards attendee from LGT Wealth Management to the meeting.	
<b>1.2.0</b>	<b>Apologies</b> Led by Hilary Jones  Apologies were received from: <ul style="list-style-type: none"> <li>• David Donegan, Chief Executive Officer</li> <li>• Anne Carey, Chief Operating Officer</li> <li>• Carl James, Executive Director of Strategic Transformation, Planning and Digital/Deputy Chief Executive Officer (Interim)</li> <li>• Paul Wilkins, Charity Director</li> <li>• Barry Williams, Senior Finance Business Partner</li> </ul>	
<b>1.3.0</b>	<b>Declarations of Interest</b> Led by Hilary Jones  No Declarations of Interest were declared.	
<b>1.4.0</b>	<b>Draft Minutes from the meeting held on 19 September 2024</b> Led by Hilary Jones	

	The Committee <b>APPROVED</b> the minutes from 19 September 2024, as a true and accurate record of the meeting.	
<b>1.5.0</b>	<p><b>Actions/Rolling Updates/Matters Arising</b> Led by Matthew Bunce, Executive Director of Finance and Steve Coliandris, Head of Financial Planning &amp; Reporting</p> <p>The Committee <b>NOTED</b> the updates and discussed the remaining <b>OPEN</b> actions as below:</p> <p><b>Action from 01.12.2024 (2.2.0) 1</b> The Investment Policy Workshop was delivered in February – CLOSED</p> <p><b>Action from 19.09.2024 (3.1.0) 3</b> Presentation to Velindre University NHS Trust (Performance Figures) has been included on the agenda today – CLOSED</p> <p><b>Action from 19.09.2024 (3.1.0) 4</b> Authorised Signatories. It was discussed to include David Donegan as a signatory and keep Carl James as a back up. Miranda Richards advised that 2 out of 3 are required.</p> <p><b>**ACTION**</b> Steve Coliandris &amp; Matthew Bunce to include David Donegan as a signatory and keep Carl James as a back up.</p> <p>The Committee <b>APPROVED</b> the <b>CLOSED</b> actions which would now be removed.</p>	<b>SC &amp; MB</b>
<b>2.0.0</b>	<b>LIQUIDITY MANAGEMENT REVIEW</b> Led by Steve Coliandris, Head of Financial Planning and Reporting	
<b>2.1.0</b>	<p><b>Liquidity Management Review Report (including cash flow forecast)</b> Led by Steve Coliandris, Head of Financial Planning and Reporting</p> <p>The Chair invited Steve Coliandris to present the report.</p> <p>The Investment Committee were asked to <b>discuss</b> and <b>review</b> the current level of cash balances that is currently held in the Charity's bank account and based on the future anticipated cash flow and the advice to be provided by investment managers at today's meeting, make a decision to <b>APPROVE</b> a transfer of <b>£1m</b> into the Liquidity Account held on behalf of the Charity Investment managers which is currently offering an interest return of just less than a 5%.</p> <p>The forecast cash balance of the Charitable funds bank account is expected to be c £2.5m as at the end of March 2025, with the balance gradually reducing over the course of 2025-26 due to the high level of commitments against the Charity.</p> <p>The income target for the Charity has been set at £5m for 2025-26, however this may be seen as an ambitious target on the basis that forecast income for 2024-25 is only expected to achieve £3.3m. At this stage prior to any further approval of bids forecast expenditure commitments against the Charity is expected to be £7.5m for 2025-26.</p>	

Therefore, in order to ensure cash levels are maintained it is advised that cash needs to be held on a short term liquid basis on order to meet commitments as they fall due.

The extraordinary non recurrent income generated in 2024-25 has enabled a request to go to the Charitable Funds Committee on the 19th March to suspend £2m of expenditure for service activities which has approved Charitable Funds support. These costs will be managed within Velindre NHS Trust core funding from non-recurrent income received in year, and therefore £2m of funding earmarked to support the cancer services remaining within the Charity. This impact has been factored into the Trust's overall Financial Plan.

The Committee **DISCUSSED** and **REVIEWED** the current level of cash balances that is currently held in the Charity's bank account and based on the future anticipated cash flow and the advice provided by investment managers at today's meeting, **APPROVED** and **AGREED** to invest the £1million into the liquidity management funds.

**\*\*Action\*\*** Steve Coliandris to provide a verbal update at Charitable Funds Committee on the 19<sup>th</sup> March and request approval from that Committee.

Subject to approval by the Charitable funds Committee to suspend charges to the Charity of £2m during 2024-25, **APPROVE** a further £2m is transferred into the liquidity account.

SC

**3.0.0 INVESTMENT ADVISORS UPDATE**

Led by Miranda Richards, LGT

**3.1.0 Presentation including Performance Figures, Risk Guide, Environmental, Social and Governance Score (ESG) Reports**

Led by Miranda Richards, LGT

The Chair invited Miranda to provide an update.

The snapshot below provides details of the Trusts investment requirements and portfolio performance to 28<sup>th</sup> February 2025.

	Investment Portfolio	Liquidity Portfolio
<b>Investment objectives</b>	Growth	Yield
<b>Benchmark</b>	Income and Growth Composite Benchmark ARC Charity Steady Growth	N/A
<b>Restrictions</b>	Core Responsible Investment Screening No investment in Oil/Gas Stocks No investment in 5% Turnover from Alcohol	None
<b>Risk profile</b>	Medium –you are prepared to accept a moderate level of risk over your time horizon to achieve your goals. You understand that, in	Low –you are prepared to accept a low amount of risk to reach your goal. You would like your investments to grow

	the longer term, a higher level of risk may result in higher returns.	but you want to minimise the possibility of swings in the value of your portfolio	
<b>Income requirements</b>	No income is required from this portfolio	No income is required from this portfolio	
<b>Timescale</b>	10 years plus	3 –5 years	
<b>Capacity for loss</b>	15 -20% income loss 10 -15% capital loss	0-5% Income Loss 0-5% Capital Loss	
<b>AMC</b>	0.5%	0.2%	
	<b>Portfolio Value</b>	<b>Estimated income</b>	<b>Estimated Forward Yield</b>
<b>Velindre-Investment Portfolio</b>	£9,463,771	£276,102	2.9%
<b>Velindre-Liquidity Portfolio</b>	£7,628,442	£350,347	4.6%
	Steve Coliandris asked how the benchmark is set and Miranda Richards agreed to include these details in the presentation at the next meeting.		
	<b>**Action**</b> Miranda Richards to include benchmarking details in the presentation at the next meeting.		
	The group discussed the risk of investing into portfolio incase the need to withdraw within a short term arises. Miranda Richards will provide a variety of sustainable bond options at the next meeting.		
	<b>**Action**</b> Miranda Richards to provide a variety of sustainable bond options at the next meeting.		
	Miranda Richards presented high level portfolio activity over 3 months to 28 <sup>th</sup> February, with key extracts below:		
	<i>Positive Stock News</i>		
	<ul style="list-style-type: none"> <li>• Eli Lilly: shares have had a strong start to the years benefitting from a strong set of Q4 earnings where the key incretin franchise (Mounjaro and Zepbound) continues to deliver very strong growth and looks well placed for the years ahead as coverage grows and demand for the medicines continues to grow strongly.</li> <li>• Adyen: rose on a solid set of full year results which showed that the business continues to grow rapidly with an expanding take rate and EBITDA margins above target.</li> <li>• AstraZeneca: had a stronger month following good Q4 results with total revenue up 25% driven by strong product sales and collaboration revenue. Oncology was again a standout performer with the therapy area posting 27% growth in the quarter</li> </ul>		
	<i>Negative Stock News</i>		
	<ul style="list-style-type: none"> <li>• Orsted Trump's bearish stance on renewables, particularly offshore wind, poses a risk to Orsted's US pipeline. SOLD</li> </ul>		
<b>4.0.0</b>	<b>ADMINISTRATION AND GOVERNANCE</b>		
	Led by Steve Coliandris, Acting Deputy Director of Finance		
<b>4.1.0</b>	<b>Charitable Funds Investment Policy</b>		
	Led by Steve Coliandris, Acting Deputy Director of Finance		

MR

MR

	Steve Coliandris explained that the Investment Policy is currently in development to go to Charitable Funds Committee.	
<b>5.0.0</b>	<b>ANY OTHER BUSINESS</b>	
	None.	
<b>6.0.0</b>	<b>DATE AND TIME OF NEXT MEETING</b>	
	30th September 2025, 10:00am	
<b>7.0.0</b>	<b>CLOSE</b>	
	The meeting closed at 11:00am.	

UNCONFIRMED